PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-
drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a …

Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial
pneumonia. Idiopathic pulmonary fibrosis is often seen in elderly men who smoke. A …

Acute exacerbation is a major cause of morbidity and mortality in patients with idiopathic
pulmonary fibrosis. Although the real nature of it is still not clear and there is no proven …

Background: Up to 10% of patients with advanced non-small cell lung cancer (aNSCLC)
have pre-existing interstitial lung disease (ILD). These patients are usually excluded from …

Background and objective The efficacy and safety of nintedanib in patients with idiopathic
pulmonary fibrosis (IPF) were investigated in the placebo‐controlled INPULSIS® trials. All …

Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a severe
complication associated with a high mortality. However, evidence and guidance on …

Introduction Increased post-marketing reports of interstitial lung disease in Japan have been
recognized. An understanding of its regional groundings can be important for the global …

Nivolumab, a monoclonal antibody against human programmed death 1, was approved for
the treatment of melanoma in July 2014 in Japan. Because the Japanese phase II studies …

Background Idiopathic pulmonary fibrosis (IPF) is a cryptogenic chronic interstitial
pneumonia with progressive fibrosis and a poor prognosis. A substantial number of …

Dermatomyositis and polymyositis are rare, idiopathic inflammatory myopathies. Interstitial
lung disease is one of the most common and potentially severe extra-muscular …